NCT06689085: 52 Week Study + 24-Month Long-Term Extension of Safety, PK, & Efficacy of XYOSTED® for Testosterone Replacement in Male Adolescents With Hypogonadism

Sponsor: Halozyme Therapeutics. Phase: PHASE3. Conditions: Hypogonadism, Male